CNTB

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and immunologic diseases. Headquartered in San Diego, California, with research facilities in Suzhou, China, the company leverages its expertise in T cell biology and immune modulation. Connect Biopharma's lead product candidate, CBP-201, is an anti-IL-4Rα antibody being developed for atopic dermatitis and other allergic inflammatory conditions. The company has additional programs targeting various immune-mediated diseases using its proprietary technology platforms. Connect Biopharma utilizes a dual-geography strategy, conducting clinical development in both China and the United States to accelerate timelines and access diverse patient populations.